Publication Name	World Journal of Virology
Manuscript ID	98765
Country	Qatar

Received	2024-07-04 19:36
Peer-Review Started	2024-07-04 19:36
To Make the First Decision
Return for Revision	2024-10-22 08:38
Revised	2024-11-04 05:21
Second Decision	2024-11-18 02:44
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-11-19 10:16
Articles in Press	2024-11-19 10:16
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-11-21 00:41
Publish the Manuscript Online	2024-11-28 03:06

ISSN	2220-3249 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Virology
Manuscript Type	Editorial
Article Title	Dexamethasone in coronavirus disease 2019 care: Dosage and utilization insights
Manuscript Source	Invited Manuscript
All Author List	Laiba Shamim, Imshaal Musharaf and Abdulqadir J Nashwan
Funding Agency and Grant Number
Corresponding Author	Abdulqadir J Nashwan, PhD, Department of Nursing and Midwifery Research, Hamad Medical Corporation, Rayyan Road, Doha 3050, Qatar. anashwan@hamad.qa
Key Words	COVID-19; Severe acute respiratory syndrome; Corticosteroid; Dexamethasone; Anti-inflammatory
Core Tip	This editorial evaluates a meta-analysis comparing high-dose and low-dose dexamethasone in the treatment of coronavirus disease 2019 (COVID-19) patients. The study reveals no significant differences in adverse effects and mortality between the dosing regimens. In line with the current guidelines, the study favors using low-dose dexamethasone but highlights the call for additional research on high-dose dexamethasone’s benefits. The study includes limitations such as a lack of long-term data and heterogeneity of the included studies. It is crucial to address these gaps in the future to optimize treatment strategies for COVID-19.
Publish Date	2024-11-28 03:06
Citation	<p>Shamim L, Musharaf I, Nashwan AJ. Dexamethasone in coronavirus disease 2019 care: Dosage and utilization insights. <i>World J Virol</i> 2025; 14(1): 98765</p>
URL	https://www.wjgnet.com/2220-3249/full/v14/i1/98765.htm
DOI	https://dx.doi.org/10.5501/wjv.v14.i1.98765

Full Article (PDF)	WJV-14-98765-with-cover.pdf
Manuscript File	98765_Auto_Edited_041222.docx
Answering Reviewers	98765-answering-reviewers.pdf
Audio Core Tip	98765-audio.m4a
Conflict-of-Interest Disclosure Form	98765-conflict-of-interest-statement.pdf
Copyright License Agreement	98765-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	98765-non-native-speakers.pdf
Peer-review Report	98765-peer-reviews.pdf
Scientific Misconduct Check	98765-scientific-misconduct-check.png
Scientific Editor Work List	98765-scientific-editor-work-list.pdf
CrossCheck Report	98765-crosscheck-report.png
CrossCheck Report	98765-crosscheck-report.pdf